证券代码：600513 证券简称：联环药业 公告编号：2025-101 江苏联环药业股份有限公司 投资者关系活动记录表 | | 特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | □新闻发布会 路演活动 | | 类别 | □现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与单位名称 | 信达澳银基金、天风证券、东方财富证券、中原自营、PCCW、 | | | 江苏高投、茂典资产、国诚投资、高道家族办公室、海能 | | | 投资、上海嘉世私募、正淄资管、兆昂投资、禾升投资、 | | | 尚欣投资、善达投资、秋阳予梁投资、聚正投资、宝屹投 | | | 资、俊远投资、涌融私募、华民投资、萧峰基金、浙农投 | | | 资 | | 时间 | 2025 年 12 月 24 日 | | 地点 | 上海 | | | 董事长兼董事会秘书：钱振华先生 董事兼总经理：牛犇先生 | | 上市公司接待人 | | | | 财务总监：薛昊先生 | | 员姓名 | 投发部负责人兼证券事务代表：葛楷先生 | | | 临床医学部经理：谭琼女士 1、问：公 ...

每经AI快讯，联环药业（SH 600513，收盘价：18.15元）发布公告称，2025年12月24日，联环药业接受 信达澳银基金等投资者调研，公司董事长兼董事会秘书钱振华等人参与接待，并回答了投资者提出的问 题。 （记者 王晓波） 2024年1至12月份，联环药业的营业收入构成为：医药流通占比59.36%，医药制造占比40.38%，其他业 务占比0.26%。 每经头条（nbdtoutiao）——微信聊天遭老板监视，杀毒软件"失明"，员工隐私被系统性采集！软件商 公开售卖"监控神器"，称已服务多家企业 截至发稿，联环药业市值为52亿元。 ...

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. announced that its subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the supplementary application of atropine sulfate injection [2] Group 1 - The approval is a significant regulatory milestone for the company, indicating progress in its product development and compliance with national standards [2] - Atropine sulfate injection is likely to enhance the company's product portfolio and potentially increase market competitiveness [2]

Group 1 - Shareholder of Okoyi plans to reduce holdings by up to 1.89% of the company's shares, amounting to a maximum of 3 million shares due to personal funding needs [1] - Tianchuang Fashion is planning a change in control, leading to continued suspension of its stock trading, expected to last no more than 3 trading days [2] - China Electric Power Construction Company reported a new contract amount of 10,317.55 billion yuan for the first 11 months of 2025, a year-on-year decrease of 1.65% [3] Group 2 - Pilin Bio's wholly-owned subsidiary received approval for a clinical trial of a drug, indicating progress in its product development [4] - Yihong Medical obtained two medical device registration certificates for diagnostic kits, enhancing its product portfolio [5] - Aohong Electronics plans to use up to 450 million yuan of idle fundraising for cash management, targeting safe and liquid financial products [6] Group 3 - China Electric Power Construction signed a contract worth approximately 6.626 billion yuan for a natural gas booster station project in Turkey, with a construction period of about 55 months [7] - Baosheng Co. won a bid for a power cable project in Singapore, valued at around 1.2 billion yuan, marking the largest overseas order in its history [8] - *ST Xinyan's stock will resume trading on December 24, 2025, following a capital increase plan that will raise its total share capital to 3.29 billion shares [9] Group 4 - Ningbo Construction's subsidiary signed a construction contract worth 428 million yuan for an engineering project with a duration of 990 days [11] - Lianhuan Pharmaceutical's subsidiary received approval for a drug that passed the consistency evaluation for generic drugs, enhancing its market competitiveness [12] - Zhongjie Automotive received a project designation for a new electric air conditioning compressor, with expected sales of approximately 29.86 million USD over its lifecycle [13] Group 5 - Biopharmaceuticals' major shareholder plans to increase holdings by 50 million to 100 million yuan, indicating confidence in the company's future [14] - Haizheng Pharmaceutical's subsidiary received approval for a veterinary drug product, expanding its product offerings in the animal health sector [15] - *ST Songfa's subsidiary signed contracts for the construction of 8 vessels, with a total contract value between 200 million to 400 million USD [16] Group 6 - Shandong Pharmaceutical Glass announced the resignation of its chairman due to age reasons, indicating a potential leadership transition [17] - Xinno Wei's subsidiary received approval for a clinical trial of a monoclonal antibody drug, indicating advancements in its drug development pipeline [18] - Ningbo Huaxiang's subsidiary secured an order for robot joints, expected to positively impact future business performance [19][20] Group 7 - China Resources Double Crane's subsidiary received approval for a clinical trial of a drug aimed at treating a genetic eye disease, reflecting ongoing R&D efforts [21] - Huaxin Technology's shareholders set a transfer price of 56.69 yuan per share for a block of shares, indicating active shareholder engagement [22] - Xinhua Net announced the resignation of its president due to job relocation, suggesting potential changes in management [23] Group 8 - Taiji Group plans to transfer a 40% stake in a subsidiary to focus on its core pharmaceutical business, enhancing operational efficiency [24] - Huaxin Construction's shareholder plans to increase holdings by 200 million to 400 million yuan, reflecting confidence in the company's prospects [25] - Dongjie Intelligent is planning to issue shares and cash for asset acquisition, with stock trading suspended until further notice [26] Group 9 - Wanrun New Energy was designated as a delivery warehouse for lithium carbonate futures, indicating its strategic position in the market [27] - Prolo Pharmaceutical's subsidiary received a drug registration certificate for an influenza treatment, expanding its product range [28] - Saiwu Technology invested 5 million yuan in a private equity fund focused on smart vehicles and energy innovation, indicating strategic investment in growth sectors [29] Group 10 - Bohui Innovation's subsidiary received approval for a clinical trial of an immunoglobulin drug, indicating progress in its product development [30] - Bohui Innovation's subsidiary also received a drug registration certificate for a coagulation factor product, enhancing its therapeutic offerings [31] - Hanghua Co. plans to allocate 146 million yuan of surplus fundraising for a new green printing materials project, reflecting a commitment to sustainability [32] Group 11 - Nova Star Cloud obtained a loan commitment letter from a bank for a share repurchase plan, indicating financial support for its capital management strategy [33] - Jimin Health established a joint venture for technology innovation, indicating a strategic move to enhance its technological capabilities [34] - Huili Pharmaceutical received a drug registration certificate for a medication used in treating digestive ulcers, expanding its product portfolio [35]

证券代码：600513 证券简称：联环药业 公告编号：2025-100 江苏联环药业股份有限公司 关于公司原料药产品左炔诺孕酮通过世界卫生组织 预认证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏联环药业股份有限公司（以下简称"公司"）收到世界卫生组 织（WHO)通知，公司原料药产品左炔诺孕酮（APIMF484,WHOAPI-484）（以下简 称"该产品"）通过世界卫生组织的预认证（PQ）。世界卫生组织已经正式将 该产品列入国际组织及公立机构采购范围。 该产品此前通过了世界卫生组织预认证的现场检查，详情请见公司于 2025 年 11 月 11 日披露的公告（公告编号:2025-084）。截至本公告披露日，该产品 的药品主文件（DMF）审评也已通过，现已完全通过世界卫生组织预认证。 特此公告。 江苏联环药业股份有限公司董事会 2025 年 12 月 24 日 1 本次通过预认证不会对公司当期经营业绩产生重大影响。国际业务易受海 外市场环境变化、汇率波动等因素影响，未来产品销售订单存在不确定性。敬 请广大投资者 ...

一、药品基本信息 1 | 生产企业 | 名称：新乡市常乐制药有限责任公司 | | | --- | --- | --- | | | 地址：河南省辉县市东郊 | 根据《中华人民共和国药品管理 | | | | 法》、《国务院关于改革药品医疗 | | | 根据《中华人民共和国药品管理 | 器械审评审批制度的意见》（国发 | | | | 〔2015〕44 号）、《关于仿制药质 | | | 法》、《国务院关于改革药品医疗 | 量和疗效一致性评价工作有关事 | | | 器械审评审批制度的意见》（国发 | | | | 〔2015〕44 号）、《关于仿制药质 | 项的公告》（2017 年第 100 号）和 | | | | 《国家药监局关于开展化学药品 | | | 量和疗效一致性评价工作有关事 | 注射剂仿制药质量和疗效一致性 | | | 项的公告》（2017 年第 100 号）和 | | | | | 评价工作的公告》（2020 年第 62 | | | 《国家药监局关于开展化学药品 | | | | 注射剂仿制药质量和疗效一致性 | 号）的规定，经审查，本品通过仿 | | 审批结论 | 评价工作的公告》（2020 年第 62 | ...

Core Viewpoint - The company, Lianhuan Pharmaceutical (600513.SH), has received notification from the World Health Organization (WHO) that its active pharmaceutical ingredient, Levonorgestrel (APIMF484, WHO API-484), has passed the WHO prequalification (PQ) process and is now included in the procurement scope of international organizations and public institutions [1] Group 1 - The product has successfully passed the WHO prequalification site inspection [1] - As of the date of this announcement, the Drug Master File (DMF) review for the product has also been completed [1] - The product is now fully prequalified by the WHO [1]

Core Viewpoint - The company, Lianhuan Pharmaceutical, has received notification from the World Health Organization (WHO) that its raw material drug, Levonorgestrel, has passed the WHO prequalification, allowing it to be included in procurement by international organizations and public institutions [1] Group 1 - The company announced that its Levonorgestrel product is now recognized by the WHO, expanding its market potential [1] - The company's subsidiary, Changle Pharmaceutical, has received approval from the National Medical Products Administration for a supplemental application regarding Atropine Sulfate Injection, which includes the addition of a new specification of 1ml: 0.5mg [1] - The approval also pertains to the consistency evaluation of the quality and efficacy of the generic drug [1]

Core Viewpoint - The company, Lianhuan Pharmaceutical (600513.SH), announced that its subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the supplementary application of Atropine Sulfate Injection [1] Group 1 - Atropine Sulfate Injection is primarily used for various visceral spasms, such as gastrointestinal colic and bladder irritability [1] - The drug is also indicated for pre-anesthesia medication, severe sweating and salivation, and bradyarrhythmias caused by excessive vagal nerve stimulation [1] - Additionally, it can be used for shock treatment and to counteract poisoning from organophosphate esters [1]

Core Viewpoint - The company, Lianhuan Pharmaceutical, has received notification from the World Health Organization (WHO) that its active pharmaceutical ingredient, Levonorgestrel, has passed the WHO prequalification process [1] Group 1: WHO Prequalification - The product Levonorgestrel has successfully undergone on-site inspection and the Drug Master File (DMF) review by the WHO, achieving full prequalification [1] - This prequalification is expected to enhance the company's credibility in the global market [1] Group 2: Financial Impact - The prequalification is not anticipated to have a significant impact on the company's current operating performance [1] - Future sales orders for the product remain uncertain, indicating potential variability in revenue generation [1]